One shot, two protections? new trial combines dengue and chikungunya vaccines

NCT ID NCT06973772

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Butantan Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This Phase 3 trial will test whether giving the dengue and chikungunya vaccines at the same time is as safe and effective as giving them separately. The study involves 900 healthy adults aged 18 to 59 who have never been exposed to either virus. Researchers will measure immune responses and track any side effects over the study period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Live attenuated dengue vaccine (serotypes 1-4) and live attenuated chikungunya vaccine (VLA1555)
What this could lead to: If successful, this could show that a single visit for both vaccines is safe and effective, simplifying protection against two mosquito-borne diseases.
What could go wrong: This is a Phase 3 trial, but results may not apply to people with prior exposure to these viruses. Co-administration could also cause more side effects or weaker immune responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chikungunya prevention target dengue disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA DENGUE

Contacts and locations

Locations

Centro Médico de São Francisco

Curitiba, Paraná, 80810-050, Brazil
Centro de Pesquisa Inova

Toledo, Paraná, 85902-010, Brazil
Hospital Escola da Universidade Federal de Pelotas

Pelotas, Rio Grande do Sul, 96040-010, Brazil
Hospital São Vicente de Paulo

Passo Fundo, Rio Grande do Sul, 99010-080, Brazil
Instituto de Pesquisa em AIDS do Estado do Rio Grande do Sul - IPARGS

Porto Alegre, Rio Grande do Sul, 91350-180, Brazil
Reumacenter

Porto Alegre, Rio Grande do Sul, 90480-000, Brazil
UBEA - União Brasileira de Educação e Assistência Hospital São Lucas da PUCRS

Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.